vs

Side-by-side financial comparison of HARTE HANKS INC (HHS) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is the larger business by last-quarter revenue ($44.6M vs $39.9M, roughly 1.1× HARTE HANKS INC). HARTE HANKS INC runs the higher net margin — 5.5% vs -90.4%, a 96.0% gap on every dollar of revenue. On growth, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. posted the faster year-over-year revenue change (13.8% vs -15.4%). HARTE HANKS INC produced more free cash flow last quarter ($-686.0K vs $-19.9M). Over the past eight quarters, PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s revenue compounded faster (7.3% CAGR vs -6.4%).

Harte Hanks is a global marketing services company headquartered in Boston, Massachusetts. Harte Hanks services include analytics, strategy, marketing technology, creative services, digital marketing, customer care, direct mail, logistics, and fulfillment.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

HHS vs PACB — Head-to-Head

Bigger by revenue
PACB
PACB
1.1× larger
PACB
$44.6M
$39.9M
HHS
Growing faster (revenue YoY)
PACB
PACB
+29.2% gap
PACB
13.8%
-15.4%
HHS
Higher net margin
HHS
HHS
96.0% more per $
HHS
5.5%
-90.4%
PACB
More free cash flow
HHS
HHS
$19.2M more FCF
HHS
$-686.0K
$-19.9M
PACB
Faster 2-yr revenue CAGR
PACB
PACB
Annualised
PACB
7.3%
-6.4%
HHS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HHS
HHS
PACB
PACB
Revenue
$39.9M
$44.6M
Net Profit
$2.2M
$-40.4M
Gross Margin
37.1%
Operating Margin
-0.3%
-92.3%
Net Margin
5.5%
-90.4%
Revenue YoY
-15.4%
13.8%
Net Profit YoY
-1802.7%
EPS (diluted)
$0.30
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HHS
HHS
PACB
PACB
Q4 25
$39.9M
$44.6M
Q3 25
$39.5M
$38.4M
Q2 25
$38.6M
$39.8M
Q1 25
$41.6M
$37.2M
Q4 24
$47.1M
$39.2M
Q3 24
$47.6M
$40.0M
Q2 24
$45.0M
$36.0M
Q1 24
$45.4M
$38.8M
Net Profit
HHS
HHS
PACB
PACB
Q4 25
$2.2M
$-40.4M
Q3 25
$-2.3M
$-38.0M
Q2 25
$-335.0K
$-41.9M
Q1 25
$-392.0K
$-426.1M
Q4 24
$2.4M
Q3 24
$142.0K
$-60.7M
Q2 24
$-27.8M
$-173.3M
Q1 24
$-171.0K
$-78.2M
Gross Margin
HHS
HHS
PACB
PACB
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Q1 24
29.1%
Operating Margin
HHS
HHS
PACB
PACB
Q4 25
-0.3%
-92.3%
Q3 25
1.3%
-101.1%
Q2 25
0.1%
-112.8%
Q1 25
-0.1%
-1154.5%
Q4 24
-3.3%
-390.1%
Q3 24
4.0%
-160.3%
Q2 24
3.0%
-488.3%
Q1 24
0.8%
-209.6%
Net Margin
HHS
HHS
PACB
PACB
Q4 25
5.5%
-90.4%
Q3 25
-5.8%
-98.9%
Q2 25
-0.9%
-105.4%
Q1 25
-0.9%
-1146.8%
Q4 24
6.0%
Q3 24
0.3%
-151.9%
Q2 24
-61.8%
-481.3%
Q1 24
-0.4%
-201.4%
EPS (diluted)
HHS
HHS
PACB
PACB
Q4 25
$0.30
$-0.11
Q3 25
$-0.31
$-0.13
Q2 25
$-0.05
$-0.14
Q1 25
$-0.05
$-1.44
Q4 24
$-0.31
$-0.44
Q3 24
$0.02
$-0.22
Q2 24
$-3.84
$-0.64
Q1 24
$-0.02
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HHS
HHS
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$5.6M
$279.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$20.5M
$5.3M
Total Assets
$91.8M
$784.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HHS
HHS
PACB
PACB
Q4 25
$5.6M
$279.5M
Q3 25
$6.5M
$298.7M
Q2 25
$4.8M
$314.7M
Q1 25
$9.0M
$343.1M
Q4 24
$9.8M
$389.9M
Q3 24
$5.9M
$471.1M
Q2 24
$11.0M
$509.8M
Q1 24
$11.5M
$561.9M
Stockholders' Equity
HHS
HHS
PACB
PACB
Q4 25
$20.5M
$5.3M
Q3 25
$19.9M
$36.1M
Q2 25
$22.2M
$61.5M
Q1 25
$21.4M
$91.6M
Q4 24
$21.7M
$506.6M
Q3 24
$21.0M
$453.1M
Q2 24
$20.6M
$492.7M
Q1 24
$20.0M
$649.0M
Total Assets
HHS
HHS
PACB
PACB
Q4 25
$91.8M
$784.1M
Q3 25
$92.7M
$803.2M
Q2 25
$95.0M
$825.5M
Q1 25
$100.6M
$860.8M
Q4 24
$101.8M
$1.3B
Q3 24
$108.1M
$1.5B
Q2 24
$109.7M
$1.5B
Q1 24
$113.4M
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HHS
HHS
PACB
PACB
Operating Cash FlowLast quarter
$737.0K
$-19.1M
Free Cash FlowOCF − Capex
$-686.0K
$-19.9M
FCF MarginFCF / Revenue
-1.7%
-44.6%
Capex IntensityCapex / Revenue
3.6%
1.9%
Cash ConversionOCF / Net Profit
0.33×
TTM Free Cash FlowTrailing 4 quarters
$-4.5M
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HHS
HHS
PACB
PACB
Q4 25
$737.0K
$-19.1M
Q3 25
$3.2M
$-18.7M
Q2 25
$-4.8M
$-29.4M
Q1 25
$-818.0K
$-44.1M
Q4 24
$4.0M
$-30.6M
Q3 24
$-2.9M
$-45.5M
Q2 24
$1.6M
$-54.3M
Q1 24
$-5.7M
$-75.7M
Free Cash Flow
HHS
HHS
PACB
PACB
Q4 25
$-686.0K
$-19.9M
Q3 25
$2.2M
$-18.8M
Q2 25
$-5.1M
$-29.9M
Q1 25
$-923.0K
$-45.4M
Q4 24
$3.4M
$-32.3M
Q3 24
$-4.9M
$-46.3M
Q2 24
$926.0K
$-55.7M
Q1 24
$-6.2M
$-79.6M
FCF Margin
HHS
HHS
PACB
PACB
Q4 25
-1.7%
-44.6%
Q3 25
5.5%
-48.9%
Q2 25
-13.1%
-75.3%
Q1 25
-2.2%
-122.3%
Q4 24
7.3%
-82.3%
Q3 24
-10.2%
-115.7%
Q2 24
2.1%
-154.8%
Q1 24
-13.7%
-205.0%
Capex Intensity
HHS
HHS
PACB
PACB
Q4 25
3.6%
1.9%
Q3 25
2.5%
0.2%
Q2 25
0.6%
1.4%
Q1 25
0.3%
3.7%
Q4 24
1.3%
4.1%
Q3 24
4.0%
2.0%
Q2 24
1.5%
4.1%
Q1 24
1.2%
10.0%
Cash Conversion
HHS
HHS
PACB
PACB
Q4 25
0.33×
Q3 25
Q2 25
Q1 25
Q4 24
-12.93×
Q3 24
-20.76×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HHS
HHS

Fulfillment And Logistics Services$17.3M43%
Customer Care$13.7M34%
Other$8.9M22%

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons